Senior Field Medical Lead — Rare Diseases (Europe)

SLB; San Donato Milanese; Ibrido; EUR 100.000 - 130.000; Tempo pieno

Descrizione del lavoro

A leading pharmaceutical company is seeking a Medical Director for Field Medical Affairs, focusing on rare diseases. This hybrid position involves strategic medical planning and field engagement across Europe. Candidates should have a strong background in clinical practice, with at least 12 years of experience in the pharmaceutical industry. Fluency in English is essential, and prior experience in Medical Affairs or as a Medical Science Liaison is advantageous. Travel up to 50% is expected to enhance partnerships that improve patient outcomes.

Competenze

• Minimum 12 years of experience in clinical practice, managed care, or the pharmaceutical industry.
• At least 2 years of experience in Medical Affairs.
• Experience as a Medical Science Liaison or in similar roles is a plus.
• Ability to travel up to 50%.

Mansioni

• Leading scientific discussions with healthcare professionals.
• Evaluating health technology assessments and reimbursement pathways.
• Responding to medical inquiries accurately.
• Collaborating to support speaker training and promotional review.
• Supporting post-approval clinical trials from design to reporting.

Conoscenze

Strategic problem solving

Building trusted relationships

Navigating complex environments

Translating clinical data

Fluency in English

Experience in Medical Affairs

Knowledge of European healthcare systems

Formazione

Advanced clinical or scientific degree (MD, DO, PharmD, or PhD)

Descrizione del lavoro

A leading pharmaceutical company is seeking a Medical Director for Field Medical Affairs, focusing on rare diseases. This hybrid position involves strategic medical planning and field engagement across Europe. Candidates should have a strong background in clinical practice, with at least 12 years of experience in the pharmaceutical industry. Fluency in English is essential, and prior experience in Medical Affairs or as a Medical Science Liaison is advantageous. Travel up to 50% is expected to enhance partnerships that improve patient outcomes.